PMID- 30828025
OWN - NLM
STAT- MEDLINE
DCOM- 20190320
LR  - 20190320
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 139
IP  - 3
DP  - 2019
TI  - [Adverse Events after the Introduction of Quadrivalent Influenza Vaccine in 
      Comparison with AH1pdm Vaccine (2009) in Japan].
PG  - 469-474
LID - 10.1248/yakushi.18-00160 [doi]
AB  - Inactivated quadrivalent influenza vaccine (IIV4) has been used as seasonal 
      influenza vaccine since 2016 in Japan. This study examined the safety of IIV4 in 
      comparison with the AH1pdm monovalent vaccine used for novel influenza in 2009. 
      Questionnaire surveillance associated with adverse events (AEs) was conducted at 
      Chiba University Hospital, Japan. After being vaccinated, all health care workers 
      (HCWs) were given a daily AEs check sheet on which they recorded solicited 
      events, the same surveillance program used after AH1pdm vaccination in 2009. The 
      frequency of injection site AEs with IIV4 was significantly higher than with the 
      monovalent vaccine, but there was no significant difference with systemic AEs. 
      Injection site and systemic AEs were reported as 83.7% and 25.5%, respectively, 
      with IIV4. The grades of AE, mild, moderate and severe, were 67.2%, 16.4% and 
      0.1% with IIV4, respectively, indicating that almost all of the AEs reported with 
      IIV4 were mild or moderate. Systemic AEs with IIV4 and monovalent vaccine were 
      reported to be 25.5% and 23.1%, respectively, with the difference not being 
      significant. The grade of AEs with IIV4, mild, moderate and severe, was 19.1%, 
      5.6% and 0.9%, respectively. The ratio of HCWs reporting AEs peaked at around 80% 
      on day 1, then decreasing to less than 5% by day 7. AEs with IIV4 were reported 
      more frequently compared with the AH1pdm monovalent vaccine. However, in 
      consideration of the grade and duration of AEs, IIV4 was a well-tolerated, safe 
      vaccine.
FAU - Yamazaki, Shingo
AU  - Yamazaki S
AD  - Division of Pharmacy, Chiba University Hospital.
FAU - Fujiwara, Mariko
AU  - Fujiwara M
AD  - Division of Infection Control, Chiba University Hospital.
FAU - Inoue, Chikako
AU  - Inoue C
AD  - Division of Infection Control, Chiba University Hospital.
FAU - Watanabe, Masaharu
AU  - Watanabe M
AD  - Division of Clinical Laboratory, Chiba University Hospital.
FAU - Takayanagi, Shin
AU  - Takayanagi S
AD  - Division of Infection Control, Chiba University Hospital.
FAU - Taniguchi, Toshibumi
AU  - Taniguchi T
AD  - Division of Infection Control, Chiba University Hospital.
FAU - Watanabe, Akira
AU  - Watanabe A
AD  - Medical Mycology Research Center, Chiba University.
FAU - Ishiwada, Naruhiko
AU  - Ishiwada N
AD  - Medical Mycology Research Center, Chiba University.
FAU - Igari, Hidetoshi
AU  - Igari H
AD  - Division of Infection Control, Chiba University Hospital.
LA  - jpn
PT  - Comparative Study
PT  - Journal Article
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Influenza Vaccines)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anaphylaxis/epidemiology/etiology
MH  - Chills/epidemiology/etiology
MH  - Female
MH  - Fever/epidemiology/etiology
MH  - Headache/epidemiology/etiology
MH  - Hospitals, University/statistics & numerical data
MH  - Humans
MH  - Influenza Vaccines/*adverse effects
MH  - Injection Site Reaction/*epidemiology/*etiology
MH  - Japan/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Myalgia/epidemiology
MH  - Nausea/epidemiology/etiology
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - AH1pdm vaccine
OT  - adverse event
OT  - quadrivalent influenza vaccine
EDAT- 2019/03/05 06:00
MHDA- 2019/03/21 06:00
CRDT- 2019/03/05 06:00
PHST- 2019/03/05 06:00 [entrez]
PHST- 2019/03/05 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
AID - 10.1248/yakushi.18-00160 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2019;139(3):469-474. doi: 10.1248/yakushi.18-00160.